BioAlliance Pharma Announces: Grant of Orphan Designation for clonidine Lauriad™ in Europe
11/3/2011 8:44:19 AM
PARIS--(BUSINESS WIRE)--Regulatory News:
BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today announced that clonidine Lauriad™ has been granted orphan designation by the European Commission in the prevention of radiotherapy-induced oral mucositis in patients with head and neck cancer.
comments powered by